Clinical trials: Hepatitis; Epidemic
Chronic Hepatitis B
Residual Histological Disease Across Treatment Pathways in Chronic Hepatitis B
This retrospective, two-center observational study evaluates contemporary non-biopsy treatment pathways in treatment-naïve adults with chronic hepatitis B who underwent liver biopsy in routine clinical practice.
- Trial name
- CHB-PATH (NCT07843446)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,201 people
- Sponsor
- Istanbul Medeniyet University
Influenza Human
Field Trial of Maternal Influenza Immunization in Asia
This project is designed to assess the efficacy of immunizing women during pregnancy with influenza vaccine on the health of these women during their pregnancy and for 6 months post-partum as well as on the health of their…
- Trial name
- Mothers'Gift (NCT01034254)
- Testing
- influenza vaccine
- Where
- Nepal
- Volunteers
- 3,693 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Hepatitis C, Chronic
A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1
PPI-668 is an antiviral agent (a hepatitis C NS5A inhibitor) that is being developed as a potential treatment for hepatitis C virus infection.
- Trial name
- NCT01448200
- Testing
- PPI-668
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Presidio Pharmaceuticals, Inc.
Hepatitis C, Chronic
Levels of Interleukin-6 andTransforming Growth Factor Beta in HCV Patients Sera
Hepatitis C virus (HCV) infection is associated with significant morbidity and mortality owing to progression of a high percentage (85%) of HCV infected patients to chronic hepatitis, which might lead to the development of liver…
- Trial name
- NCT03882307
- Testing
- sofosbuvir and daclatasvir
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
HBV (Hepatitis B Virus), Hepatitis B
Lamivudine and Adefovir to Treat Chronic Hepatitis B
This study will evaluate the safety and effectiveness of lamivudine plus adefovir versus adefovir alone to treat chronic hepatitis B infection.
- Conditions
- HBV (Hepatitis B Virus), Hepatitis B, Hepatitis
- Trial name
- NCT00023309
- Testing
- Lamivudine and adefovir, Adefovir alone
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis C
Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.
- Trial name
- NCT00591214
- Testing
- MP-424 (Telaprevir)
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis B
A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)
The purpose of this study is to demonstrate the durability of protection against hepatitis B virus (HBV) infection approximately 8-9 years after vaccination with Vaxelis®.
- Trial name
- NCT04490499
- Testing
- HBVAXPRO™
- Where
- 10 sites in Finland
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Acute Hepatitis C, HIV
The Natural History and Treatment of Acute Hepatitis C Virus (HCV) in HIV-positive Individuals
The aim of the study is to investigate the epidemiology, natural history and treatment outcomes of acute hepatitis C (HCV) infection.
- Trial name
- PROBE-C (NCT01289652)
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Benedetta Mattioli
Hepatitis B, Chronic
A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)
This study is being done to compare the safety and efficacy of PEG-Intron™ to that of PEGASYS™ in participants with chronic hepatitis B (hepatitis B envelope antigen [HBeAg] positive or negative) who have not previously been…
- Trial name
- NCT01641926
- Testing
- PEG-Intron™, PEGASYS™
- Volunteers
- 402 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Hiv
Acceptability, Feasibility, and Preliminary Impact of a Web-based, HIV Prevention Toolkit With Cisgender Male Couples in Lima, Peru
This digital couples-based HIV/STI prevention intervention project will determine preliminary efficacy to improve uptake of evidence-based strategies and a tailored prevention plan among cisgender male couples who are in a…
- Conditions
- HIV Infections, Hiv, Sexually Transmitted Infections (Not HIV or Hepatitis), Sexually Transmitted Diseases
- Trial name
- NCT05873855
- Testing
- Para ti, para mi, para nosotros (P3), Waitlist Control Para ti, para mi, para nosotros (P3)
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- Florida International University
Hepatitis C
Infliximab Treatment Along With Pegylated Interferon and Ribavirin in the Treatment of Hepatitis C
The aim of the study is to investigate in subjects receiving their first course of peg-interferon α-2b plus ribavirin therapy for chronic HCV infection
- Trial name
- PARTNER (NCT00512278)
- Testing
- Infliximab
- Where
- 7 sites in United States
- Volunteers
- 146 people
- Sponsor
- Nizar Zein
Vaccine Adverse Reaction, Vaccine Reaction
Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants
This trial is open label, comparative, randomized, phase I/II study, experimental, randomized, open-label, three arm parallel group study.
- Trial name
- NCT06690515
- Testing
- DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A, DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B, Registered DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac)®
- Where
- 3 sites in Indonesia
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
HBV
Access HBV Assays - European Union (EU) Clinical Trial Protocol -
The objective of this protocol is the collection and testing of clinical samples to determine the clinical performance of the Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer.
- Trial name
- NCT04904835
- Testing
- Access HBV serological marker assays on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
- Where
- 5 sites in France
- Volunteers
- 21,210 people
- Sponsor
- Beckman Coulter, Inc.
Severe Alcoholic Hepatitis
Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis
After successful screening, first the investigators first treat patients of severe alcoholic hepatitis with steroids for 7 days.
- Trial name
- NCT01820208
- Testing
- G-CSF
- Where
- India
- Volunteers
- 28 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Chronic Hepatitis C
The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C
The efficacy of combination antiviral therapy for chronic hepatitis C is influenced by many factors. Important patient-specific factors include, age, gender, race, body weight.
- Trial name
- NCT01464008
- Testing
- Pegylated interferon alfa-2a and ribavirin
- Where
- China
- Volunteers
- 297 people
- Sponsor
- Beijing Ditan Hospital
Vaccination
Evaluation of the Safety and Immunogenicity of Hepatitis A Vaccine
Subjects will be recruited and divided into 3 groups: 1. Hepatitis A（Live）Vaccine，Freeze-dried produced by Changchun Institute of Biological Products Co., Ltd 2.
- Trial name
- NCT04612634
- Testing
- Hepatitis A (Live) Vaccine, Freeze-dried produced by Changchun, Hepatitis A (Live) Vaccine, Freeze-dried produced by Zhejiang, Hepatitis A (Live) Vaccine, Freeze-dried produced by the Institute of Medical Biology, CAMS
- Where
- 2 sites in China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Chronic Hepatitis C
Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial
Data have suggested that consensus interferon (CIFN) has greater antiviral activity in vitro compared with interferon alfa-2a or alfa-2b.
- Trial name
- NCT00211692
- Testing
- consensus interferon (Interferon Alfacon-1) and ribavirin, Consensus Interferon alfa (CIFN) and ribavirin
- Volunteers
- 64 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Chronic Hepatitis C, Neoplasms
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
Combination therapy with pegylated interferon-alpha plus ribavirin has greatly improved the treatment efficacy and is the mainstream of treatment for chronic hepatitis C infection.
- Trial name
- NCT00630084
- Testing
- pegylated interferon alpha 2a and plus ribavirin
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).
The effects of treatment with different doses of PEGASYS in combination with different doses of ribavirin will be evaluated in patients with CHC genotype 1 who have a high viral titer, body weight greater than 85kg (187lbs) and…
- Trial name
- NCT00077649
- Testing
- ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Chronic Hepatitis B
Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy
Previous studies dealt with patients who maintained antiviral drugs for 2 ~ 6 months after final chemotherapy and they revealed that many of the patients who stopped preemptive antiviral drug within 6 months experienced viral…
- Trial name
- NCT02056548
- Volunteers
- 126 people
- Sponsor
- Seoul St. Mary's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.